# HOSPITAL MEDICINES LIST
# RESTRICTIONS CHECKLIST



Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

## Nivolumab

**INITIATION – unresectable or metastatic melanoma**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

**and**

- ○ The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV

**and**

- ○ Baseline measurement of overall tumour burden is documented clinically and radiologically

**and**

- ○ The individual has ECOG performance 0-2

**and**

- ○ The individual has not received funded pembrolizumab

**or**

- ○ The individual has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance

**and**

- ○ The cancer did not progress while the individual was on pembrolizumab

**and**

- ○ The individual has been diagnosed in the metastatic or unresectable stage III or IV setting

**or**

- ○ The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor

**or**

- ○ The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor

**and**

- ○ The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor

**and**

- ○ The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor



I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

## Nivolumab *- continued*

**CONTINUATION – unresectable or metastatic melanoma, less than 24 months on treatment**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

**and**

- ○ The individual's disease has had a complete response to treatment
  **or**
- ○ The individual's disease has had a partial response to treatment
  **or**
- ○ The individual has stable disease

**and**

- ○ Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

**or**

- ○ The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression

**and**

- ○ The individual has signs of disease progression

**and**

- ○ Disease has not progressed during previous treatment with nivolumab

**CONTINUATION – unresectable or metastatic melanoma, more than 24 months on treatment**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Prescribed by, or recommended by a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

**and**

- ○ The individual has been on treatment for more than 24 months

**and**

- ○ The individual's disease has had a complete response to treatment
  **or**
- ○ The individual's disease has had a partial response to treatment
  **or**
- ○ The individual has stable disease

**and**

- ○ Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period

**or**

- ○ The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression

**and**

- ○ The individual has signs of disease progression

**and**

- ○ Disease has not progressed during previous treatment with nivolumab

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

## Nivolumab *- continued*

**INITIATION – renal cell carcinoma, first line**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment

**or**

- ○ The patient has metastatic renal cell carcinoma

**and**

- ○ The patient is treatment naive

**and**

- ○ The patient has ECOG performance status 0-2

**and**

- ○ The disease is predominantly of clear cell histology

**and**

- ○ The patient has sarcomatoid histology

**or**

- ○ Haemoglobin levels less than the lower limit of normal

**or**

- ○ Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L)

**or**

- ○ Neutrophils greater than the upper limit of normal

**or**

- ○ Platelets greater than the upper limit of normal

**or**

- ○ Interval of less than 1 year from original diagnosis to the start of systemic therapy

**or**

- ○ Karnofsky performance score of less than or equal to 70

**and**

- ○ Nivolumab is to be used in combination with ipilimumab for the first four treatment cycles at a maximum dose of 3 mg/kg

**and**

- ○ Nivolumab is to be used at a maximum maintenance dose of 240 mg every 2 weeks (or equivalent)

**INITIATION – renal cell carcinoma, second line**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Patient has metastatic renal-cell carcinoma

**and**

- ○ The disease is of predominant clear-cell histology

**and**

- ○ Patient has ECOG performance status 0-2

**and**

- ○ Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy

**and**

- ○ Patient has not previously received a funded immune checkpoint inhibitor

**and**

- ○ Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

## Nivolumab *- continued*

**CONTINUATION – renal cell carcinoma**
Re-assessment required after 4 months
**Prerequisites** (tick boxes where appropriate)

- ○ Patient's disease has had a complete response to treatment
  **or**
- ○ Patient's disease has had a partial response to treatment
  **or**
- ○ Patient has stable disease

**and**

- ○ No evidence of disease progression

**and**

- ○ Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression



I confirm that the above details are correct:

Signed: ..... Date: .....